Cwm LLC Sells 1,220 Shares of Medpace Holdings, Inc. $MEDP

Key Points

• Cwm LLC reduced its holdings in Medpace Holdings by 15.0%, selling 1,220 shares and ending with a total of 6,927 shares worth $2,174,000.
• Insider sales saw a significant drop, with VP Susan E. Burwig selling 10,000 shares for $4.8 million, and over the last quarter, insiders sold 161,266 shares valued at $74.1 million.
• Medpace recently received mixed analyst ratings, including a downgrade from Zacks Research, while still having a consensus price target of $430.60 despite varied opinions on its performance.

Cwm LLC reduced its position in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 15.0% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,927 shares of the company's stock after selling 1,220 shares during the period. Cwm LLC's holdings in Medpace were worth $2,174,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Geneos Wealth Management Inc. lifted its holdings in shares of Medpace by 64.9% in the 1st quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after purchasing an additional 37 shares in the last quarter. Brooklyn Investment Group lifted its holdings in shares of Medpace by 244.8% in the 1st quarter. Brooklyn Investment Group now owns 100 shares of the company's stock worth $30,000 after purchasing an additional 71 shares in the last quarter. Whittier Trust Co. lifted its holdings in shares of Medpace by 47.3% in the 1st quarter. Whittier Trust Co. now owns 109 shares of the company's stock worth $33,000 after purchasing an additional 35 shares in the last quarter. IFP Advisors Inc lifted its holdings in shares of Medpace by 223.3% in the 2nd quarter. IFP Advisors Inc now owns 194 shares of the company's stock worth $61,000 after purchasing an additional 134 shares in the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Medpace in the 1st quarter worth $60,000. 77.98% of the stock is currently owned by institutional investors.

Insider Activity

In other news, VP Susan E. Burwig sold 10,000 shares of the firm's stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the completion of the sale, the vice president directly owned 57,500 shares of the company's stock, valued at $27,600,000. This trade represents a 14.81% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Stephen P. Ewald sold 3,000 shares of the firm's stock in a transaction on Monday, July 28th. The shares were sold at an average price of $450.00, for a total value of $1,350,000.00. Following the sale, the general counsel directly owned 10,343 shares of the company's stock, valued at approximately $4,654,350. This represents a 22.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 161,266 shares of company stock worth $74,111,427. 20.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. Zacks Research cut Medpace from a "strong-buy" rating to a "hold" rating in a report on Monday, September 22nd. William Blair reissued a "market perform" rating on shares of Medpace in a research report on Wednesday, July 23rd. Truist Financial increased their price target on Medpace from $298.00 to $436.00 and gave the company a "hold" rating in a research report on Wednesday, July 23rd. Jefferies Financial Group increased their price target on Medpace from $400.00 to $450.00 and gave the company a "hold" rating in a research report on Tuesday, September 9th. Finally, Cowen lowered Medpace from a "buy" rating to a "sell" rating in a research report on Wednesday, July 23rd. Two analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Reduce" and a consensus target price of $430.60.

Medpace Price Performance

Shares of Medpace stock opened at $528.07 on Friday. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $547.15. The firm has a market cap of $14.84 billion, a PE ratio of 39.26, a P/E/G ratio of 3.31 and a beta of 1.40. The stock has a fifty day moving average price of $492.23 and a 200-day moving average price of $382.32.

Medpace (NASDAQ:MEDP - Get Free Report) last announced its earnings results on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. During the same period last year, the firm posted $2.75 EPS. The business's revenue was up 14.2% compared to the same quarter last year. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.